Salmonella typhimurium A1-R targeting of a chemotherapy-resistant BRAF-V600E melanoma in a patient-derived orthotopic xenograft (PDOX) model is enhanced in combination with either vemurafenib or temozolomide. Issue 13 (3rd July 2017)

• Record Type: Journal Article
• Authors: Kawaguchi, Kei; Igarashi, Kentaro; Murakami, Takashi; Kiyuna, Tasuku; Zhao, Ming; Zhang, Yong; Nelson, Scott D.; Russell, Tara A.; Dry, Sarah M.; Singh, Arun S.; Chmielowski, Bartosz; Li, Yunfeng; Unno, Michiaki; Eilber, Fritz C.; Hoffman, Robert M.
• Is Part Of: Cell cycle. Volume 16:Issue 13(2017)
• Page Start: 1288
• Page End: 1294
• Publication Date: 2017-07-03
• Subjects: combination therapy -- drug-response -- melanoma -- nude mice -- orthotopic -- PDOX -- precision therapy -- Salmonella typhimurium A1-R -- temozolomide -- tumor regression -- vemurafenib; Cell cycle -- Periodicals; 571.84377
• DOI: 10.1080/15384101.2017.1314420
• Languages: English
• ISSNs: 1538-4101

Abstract

ABSTRACT: A metastatic melanoma obtained from the right chest wall of a patient was previously established orthotopically in the right chest wall of nude mice as a patient-derived orthotopic xenograft (PDOX) model. We previously showed that the combination of tumor-targeting Salmonella typhimurium A1-R ( S. typhimurium A1-R) and chemotherapy was highly effective against the melanoma PDOX. In the present study, we investigated the mechanism of the high efficacy of this combination. Two weeks after implantation, 40 PDOX mouse models were randomized into 4 groups of 10 mice each: untreated control (n = 10); treated with S. typhimurium A1-R (5 × 10 7 CFU/100 μl, i.v., once a week for 2 weeks, n = 10); treated with temozolomide (TEM) (25 mg/kg, p.o. for 14 consecutive days) combined with S. typhimurium A1-R (5 × 10 7 CFU/100 μl, i.v., once a week for 2 weeks, n = 10); treated with vemurafenib (VEM) (30 mg/kg, p.o., for 14 consecutive days) combined with S. typhimurium A1-R (5 × 10 7 CFU/100 μl, i.v., once a week for 2 weeks) (n = 10). On day 14 from initiation, all treatments significantly inhibited tumor growth compared with untreated control ( S. typhimurium A1-R: p < 0.01; TEM combined with S. typhimurium A1-R: p < 0.01; VEM combined with S. typhimurium A1-R: p < 0.01). Combination therapy with S. typhimurium A1-R was significantly more effective on tumor growth than S. typhimurium A1-R alone (with TEM: p < 0.01; with VEM: p < 0.01). Combination therapy significantly increased S. typhimurium A1-R tumor targeting alone ( S. typhimurium A1-R + TEM: p < 0.01, S. typhimurium A1-R + VEM: p < 0.01), relative to S. typhimurium A1-R alone, respectively. In conclusion, chemotherapy drugs promoted targeting of S. typhimurium A1-R of melanoma, thereby enhancing efficacy against the melanoma PDOX.